• Tracleer®

  (bosentan) is an oral dual endothelin receptor antagonist (ERA)

• Tracleer®

  is indicated for the treatment of PAH to improve exercise capacity and symptoms in patients with grade III functional status (see Prescribing Information)

• Tracleer®

  has demonstrated efficacy in idiopathic PAH (IPAH) and PAH secondary to scleroderma without significant interstitial pulmonary disease^2.3

• Tracleer®

  comprehensively blocks the deleterious effects of ET in-vitro and in-vivo (figure 7)

Figure 7: Comprehensive blockade of ET deleterious effects with Tracleer in-vitro and in-vivo

• Tracleer®

  is recommended as first-line treatment in PAH patients in functional class III, not responding to acute vasoreactivity testing³⁴